When Cells Die II: A Comprehensive Evaluation of Apoptosis and Programmed Cell Death

Richard A. Lockshin, Zahra Zakeri

ISBN 10: 0471219479 / ISBN 13: 9780471219477

Edité par Wiley-Liss 2004-01-20, 2004

A propos de cet article

N° de réf. du vendeur 6666-WLY-9780471219477

Détails bibliographiques

• Titre: When Cells Die II: A Comprehensive Evaluation of Apoptosis and Programmed Cell Death
• Éditeur: Wiley-Liss 2004-01-20
• Date de parution: 2004
• Langue: anglais
• ISBN à 10 chiffres: 0471219479
• ISBN à 13 chiffres: 9780471219477
• Reliure: Hardcover
• Édition: 2ème Édition
• État de l'article: New

A propos de ce titre

Synopsis

Cell death is fast becoming one of the most dynamic areas of biological research-involving as it does the study of apoptosis and programmed cell death and the role these phenomena play in development and homeostasis on the one hand, and aging and disease on the other. The profound implications for medicine and agriculture from the manipulation of these processes have spawned a deluge of research papers, articles, approaches, and methods-making it difficult for scientists to get an overview of the field.
When Cells Die II: A Comprehensive Evaluation of Apoptosis and Programmed Cell Death offers the most thorough, cutting-edge coverage of this field since publication of the acclaimed first edition. Leading international researchers present an up-to-date yet accessible survey ranging from the history of cell death science to its modern methodology. Extensively revised to include major advances in research, this new edition features relevant discussion of:
* The impact of genomics and proteomics
* Gene therapy and pharmacogenetics
* The role of mitochondria
* Caspase-independent and non-apoptotic cell death
* Evolution of mechanisms
With the manipulation of programmed cell death in clinical situations now in the foreseeable future, When Cells Die II also addresses the role of apoptosis in specific organ systems-the immune system, nervous system, and gastrointestinal tract-as well as different disease states, including viral infection, cancer, and myocardial infarct.
Expertly edited to provide detailed cross-referencing, consistency of style, and a logical progression of topics, When Cells Die II is the definitive resource for understanding current cell death science. It will prove an invaluable text for advanced undergraduate, graduate, and medical students, postdoctoral fellows, scientists, and clinicians in cell biology, immunology, developmental biology, neuroscience, and cancer research.

À propos de l?auteur

Dr. Richard Lockshin's doctoral thesis introduced the term and concept of programmed cell death, and his laboratory has been involved in several of the major advances in the field. Following his training at Harvard, he completed his postdoctoral training at the University of Edinburgh, and subsequently taught at the University of Rochester School of Medicine and Dentistry and St. John's University, where he is Professor of Biology. He has well over 100 publications on the subject, including five books. He has won several prizes for his work and has held several scientific offices, including the founding chair of the Gordon Conferences on Cell Death, and co-founder and first president of the International Cell Death Society.

Dr. Zahra Zakeri was originally trained as a geneticist and virologist and, following her post-doctoral training at Columbia University, working on germ cell development, embarked on the study of apoptosis. She has been a leader in the development of many ideas in the field, including identification of the correlation between the synthesis of growth factors and cell death, the role of cell death in congenital malformations, measurement of DNA fragmentation in situ, recognition of the role of lysosomes and macrophages in cell death and its measurement, and the relationship of cell cycle to cell death. She was a cofounder of the Gordon Conferences on Cell Death and the International Cell Death Society, of which she is currently President. She has been a featured speaker in more than 20 countries.